Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Pick Your Favored method of transportation - 2The capacity to understand people on a profound level: Exploring Life's Intricacies
- 3Family Holiday spots
- 4AbbVie plans to build out its presence in obesity market
- 5The most effective method to Look at Medical caretaker Compensations Across Various Clinics
- 'Sex and the City' star Kim Cattrall marries longtime partner Russell Thomas in intimate London wedding
- The Best 20 Photography Instagram Records to Follow
- 'All's Fair,' Ryan Murphy's new show starring Kim Kardashian, hit with scathing reviews: 'A girlboss fever dream'
- Figuring out Significant Regulations and Guidelines for Organizations
- Sophie Kinsella, 'Confessions of a Shopaholic' author, dies at 55 after battle with cancer
- Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
- Easy to understand Tech: Cell phones for Old in 2024
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
